Renal

**Localized**

- T1b or greater (has not spread beyond the kidney)
  - IRB#16576 Atezolizumab vs placebo as adjuvant therapy following nephrectomy

**Clear Cell**

- No Prior Systemic Therapy
  - IRB# 16300 Merck 3475
- Metastasectomy Candidate
  - IRB# 11283 A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a Lead-In Phase IB Dose-Escalation Portion) In Patients With Advanced Or Metastatic Renal Cell Carcinoma.
- Cytoreductive Nephrectomy Candidate
  - No trials Currently Available

**Non-Clear Cell**

- Prior Systemic Therapy
  - IRB# 16085 S1500 – Cabozantinib, Crizotinib, Savolitinib and sunitinib

**Metastatic/advanced**

- No Trials Currently Available